医保、商保、集采三重优化共振创新药板块！借道恒生创新药ETF华泰柏瑞（520500）助力布局板块修复机遇

新浪基金07-01

伴随医保目录初审结果的正式落地，“医保+商保”双目录谈判正式步入实操阶段，创新药行业正迎来政策红利集中释放周期。医保准入机制变革、商保衔接打通、集采规则优化三项制度协同推进，有效提振板块盘面活跃度。受此提振，目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞（520500）交易热度同步走高，截至今日早盘收盘，半日成交额已突破10.8亿元，达昨日全天成交额的64%，流动性优势较...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2648559040?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-01 14:54","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2648559040","market":"us","top_or_hot":-1,"title":"医保、商保、集采三重优化共振创新药板块！借道恒生创新药ETF华泰柏瑞（520500）助力布局板块修复机遇","media":"新浪基金","content":"<div>\n<p>伴随医保目录初审结果的正式落地，“医保+商保”双目录谈判正式步入实操阶段，创新药行业正迎来政策红利集中释放周期。医保准入机制变革、商保衔接打通、集采规则优化三项制度协同推进，有效提振板块盘面活跃度。受此提振，目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞（520500）交易热度同步走高，截至今日早盘收盘，半日成交额已突破10.8亿元，达昨日全天成交额的64%，流动性优势较...</p>\n\n<a href=\"https://finance.sina.com.cn/money/fund/jjh/2026-07-01/doc-inifhrqy6366719.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医保、商保、集采三重优化共振创新药板块！借道恒生创新药ETF华泰柏瑞（520500）助力布局板块修复机遇</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医保、商保、集采三重优化共振创新药板块！借道恒生创新药ETF华泰柏瑞（520500）助力布局板块修复机遇\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-01 14:54 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/money/fund/jjh/2026-07-01/doc-inifhrqy6366719.shtml><strong>新浪基金</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>伴随医保目录初审结果的正式落地，“医保+商保”双目录谈判正式步入实操阶段，创新药行业正迎来政策红利集中释放周期。医保准入机制变革、商保衔接打通、集采规则优化三项制度协同推进，有效提振板块盘面活跃度。受此提振，目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞（520500）交易热度同步走高，截至今日早盘收盘，半日成交额已突破10.8亿元，达昨日全天成交额的64%，流动性优势较...</p>\n\n<a href=\"https://finance.sina.com.cn/money/fund/jjh/2026-07-01/doc-inifhrqy6366719.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"520500","symbol_name":"恒生创新药ETF华泰柏瑞","start_time":0,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-01/doc-inifhrqy6366719.shtml","article_id":"2648559040","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648559040","pubTimestamp":1782888840,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"伴随医保目录初审结果的正式落地，“医保+商保”双目录谈判正式步入实操阶段，创新药行业正迎来政策红利集中释放周期。医保准入机制变革、商保衔接打通、集采规则优化三项制度协同推进，有效提振板块盘面活跃度。受此提振，目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞交易热度同步走高，截至今日早盘收盘，半日成交额已突破10.8亿元，达昨日全天成交额的64%，流动性优势较突出。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","520500":"恒生创新药ETF华泰柏瑞","BK1574":"生物医药B类股","06978":"永泰生物-B","BK1161":"生物科技"},"translate_title":"Medical insurance, commercial insurance, and centralized procurement triple optimization resonance innovative drug sector! Leveraging Hang Seng Innovative Drug ETF Huatai-PineBridge (520500) to help exploit sector repair opportunities","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"520500":1.5,"06978":1.5},"content_text":"伴随医保目录初审结果的正式落地，“医保+商保”双目录谈判正式步入实操阶段，创新药行业正迎来政策红利集中释放周期。医保准入机制变革、商保衔接打通、集采规则优化三项制度协同推进，有效提振板块盘面活跃度。受此提振，目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞（520500）交易热度同步走高，截至今日早盘收盘，半日成交额已突破10.8亿元，达昨日全天成交额的64%，流动性优势较突出。\n　　从产业层面看，积极信号不断显现，新药商业化落地与海外技术授权业务同步提速。近期多款自研创新药完成上市审批，5月行业完成两笔规模超百亿美元的海外BD合作，海外市场对国内新药研发实力认可度不断提高。据统计，截至今年5月末，国内药企管线对外授权总额894亿美元，已占到去年全年总额的66%，全年交易规模有望再创新高。\n　　从研发端看，创新药行业的发展动能同样充沛。2025年我国药物临床试验登记总量达5215项，首次突破5000项，较2020年实现翻倍；其中新药临床试验2997项，占比57.5%，同比增长18%。2026年前五个月，1类创新药IND申报同比增长高达30%。国产新药在国际学术会议上披露的临床数据已达到国际一流水准，产业或正从积累期迈入集中收获阶段。\n　　国金证券表示，随着国内创新药企临床管线全球竞争力持续提升、医保政策及商保对创新药加速倾斜，多家创新药企有望持续步入业绩收获期。在全球创新药资产景气度加强的背景下，当前的中国创新药板块面临基本面向上、估值向下的背离，或具备高弹性的低位投资价值。\n　　据悉，恒生创新药ETF华泰柏瑞（520500）紧密跟踪的恒生创新药指数通过QDII机制投资40家港股创新药龙头企业，主要聚焦于生物制药、化学制药及原料药等中上游创新药领域，集结了一批研发实力强劲、具备发展潜力的研发驱动型企业。该ETF规模较大、流动性较优，且支持场内T+0交易，在BD兑现、盈利拐点及政策支持背景下，或是助力布局港股创新药机遇的便捷工具。\n　　恒生创新药ETF华泰柏瑞（520500）的管理人华泰柏瑞基金是国内首批ETF管理人，在指数投资领域深耕超19年，为投资者打造了沪深300ETF华泰柏瑞（510300）、A500ETF华泰柏瑞（563360）等投向透明、交易便捷、费率低廉的指数工具。截至2026年3月末，公司旗下ETF近两年累计为持有人盈利超2234亿元，是同期A股全市场仅有的三家累计盈利超两千亿元的公募基金公司之一。\n\nMACD金叉信号形成，这些股涨势不错！\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：石秀珍 SF183","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648559040","isCrawlerRequest":true}